- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03588975
Un estudio de MACI en pacientes de 10 a 17 años con defectos condrales u osteocondrales sintomáticos de la rodilla (PEAK)
Estudio clínico de fase 3, prospectivo, abierto, aleatorizado, con control activo concurrente, longitudinal, multicéntrico, de la seguridad y eficacia de MACI en pacientes de 10 a 17 años con defectos condrales u osteocondrales sintomáticos de la rodilla debido a osteocondritis disecante o Trauma agudo
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).
After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.
All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.
Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.
Participants will be followed post-study treatment for 2 years (104 Weeks).
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Vericel Clinical Affairs
- Número de teléfono: 978-347-2876
- Correo electrónico: clinicalhotline@vcel.com
Ubicaciones de estudio
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- Stanford University School of Medicine
-
Contacto:
- Amishi Jobanputra
- Número de teléfono: 650-498-4180
- Correo electrónico: amishij@stanford.edu
-
Investigador principal:
- Kevin Shea
-
Sacramento, California, Estados Unidos, 95817
- Reclutamiento
- Shriners Hospital for Children Northern California
-
Investigador principal:
- Brian Haus
-
Contacto:
- Kory Bettencourt
- Número de teléfono: 916-453-5030,
- Correo electrónico: kbettencourt@shrinenet.org
-
Sacramento, California, Estados Unidos, 95817
- Reclutamiento
- University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
-
Investigador principal:
- Brian Haus
-
Contacto:
- Julia Martin
- Número de teléfono: 916-734-8175
- Correo electrónico: jyhmartin@health.ucdavis.edu
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Reclutamiento
- Ochsner Health System-Elmwood
-
Contacto:
- Joseph Laurent
- Número de teléfono: 504-842-0263
- Correo electrónico: Joseph.laurent@ochsner.org
-
Investigador principal:
- Brian Godshaw
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Reclutamiento
- Johns Hopkins Hospital
-
Contacto:
- Rushyuan Jay Lee, MD
- Número de teléfono: 443-997-2663
- Correo electrónico: rlee74@jhmi.edu
-
Contacto:
- Gabrielle Reichard
- Número de teléfono: 410-502-3626
- Correo electrónico: greicha1@jhmi.edu
-
Investigador principal:
- Rushyuan Jay Lee
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Reclutamiento
- University of Michigan Medsport Orthopaedic Surgery
-
Contacto:
- Christopher Ray
- Número de teléfono: 734-615-0934
- Correo electrónico: raychri@med.umich.edu
-
Investigador principal:
- Eileen Crawford
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Terminado
- Montefiore Medical Center/Albert Einstein College of Medicine
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44308
- Reclutamiento
- Akron Children's Hospital
-
Contacto:
- John Polousky, MD
- Número de teléfono: 330-543-3500
- Correo electrónico: JPolousky@akronchildrens.org
-
Investigador principal:
- John Polousky
-
Columbus, Ohio, Estados Unidos, 43202
- Reclutamiento
- The Ohio State University Jameson Crane Sports Medicine Institute
-
Contacto:
- Jenna DeFranco
- Número de teléfono: 614-293-2761
- Correo electrónico: jenna.defranco@osumc.edu
-
Investigador principal:
- Christopher Kaeding
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Penn Medicine University City
-
Contacto:
- Dorothy Brill
- Número de teléfono: 215-273-5062
- Correo electrónico: dcbrill@upenn.edu
-
Investigador principal:
- James Carey
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
-
Contacto:
- Divya Talwar
- Número de teléfono: 215-590-1527
- Correo electrónico: talward@chop.edu
-
Investigador principal:
- Theodore Ganley
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- Reclutamiento
- University Orthopedics, Inc.
-
Contacto:
- Cyndi Chrostek
- Número de teléfono: 401-318-0529
- Correo electrónico: cchrostek@brownhealth.org
-
Investigador principal:
- Nicholas Lemme
-
-
Texas
-
Houston, Texas, Estados Unidos, 77094
- Terminado
- Texas' Children Hospital
-
Plano, Texas, Estados Unidos, 75024
- Terminado
- Children's Medical Center Plano
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53201
- Reclutamiento
- Children's Hospital of Wisconsin
-
Contacto:
- John Erickson, DO
- Número de teléfono: 414-337-7325
- Correo electrónico: JErickson2@childrenswi.org
-
Investigador principal:
- John Erickson
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age 10 to 17 years at the time of planned randomization
-
Symptomatic cartilage or osteochondral defects
-
One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).
- Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
- Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
-
At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.
-
Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.
-
Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.
-
Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.
-
Written informed consent
Exclusion Criteria:
-
Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)
-
Previous investigational drug or device use within 3 months prior to Screening
-
Avascular necrosis of the target knee (other than potential OCD lesion to be treated)
-
Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate
-
ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion
-
Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)
-
Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint
-
Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)
-
Known history of septic arthritis in the index knee joint
-
Current malignancy or treatment for malignancy within the past 5 years
-
Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin
-
Females who are pregnant or lactating
-
Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:
- Any condition that has potential for negatively impacting intra or postoperative course
- Conditions that limit compliance with rehabilitation program
- Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
- Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
- Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: MACI
autologous cultured chondrocytes on porcine collagen membrane |
autologous cultured chondrocytes on porcine collagen membrane |
|
Otro: microfracture
surgical procedure |
Arthroscopic microfracture treatment |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
Periodo de tiempo: Baseline and Week 104
|
A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in KOOS-Child subscores
Periodo de tiempo: Baseline and Week 104
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
|
Change from Baseline in KOOS-Child subscores
Periodo de tiempo: Baseline and Week 52
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 52
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Treatment Emergent Adverse Events
Periodo de tiempo: Week 104
|
A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. |
Week 104
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd, Vericel Corporation
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 55-1702-1
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .